FDA Expands RINVOQ Use for Ulcerative Colitis and Crohn’s Disease Patients
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for RINVOQ (upadacitinib), broadening its use in the treatment of moderately to severely…
Read More...
Read More...
